HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hande, K. R. Search for Related Content PubMed PubMed Citation Articles by Hande, K. R.

The Importance of Drug Scheduling in Cancer Chemotherapy: Etoposide as an Example

Vanderbilt University School of Medicine, Nashville VA Medical Center, Nashville, Tennessee, USA

Key Words. Etoposide • Administration schedule • Cancer pharmacology • Bioavailability • Pharmacodynamics • Pharmacokinetics

Dr. Kenneth R. Hande, Vanderbilt University School of Medicine, Medical Oncology, 1956 The Vanderbilt Clinic, Nashville, TN 37232, USA.

Etoposide is a drug whose antineoplastic activity is dependent on the schedule of drug administration. This article reviews the rationale for a prolonged schedule of etoposide administration and the therapeutic results of use of such a schedule in the treatment of cancer. The pharmacology of etoposide is also reviewed, with particular attention paid to the pharmacokinetics of oral etoposide and etoposide plasma concentrations associated with cytotoxicity.

This article has been cited by other articles:

				L. Wang, S. Clutter, J. Benincosa, J. Fortney, and L. F. Gibson Activation of Transforming Growth Factor-{beta}1/p38/Smad3 Signaling in Stromal Cells Requires Reactive Oxygen Species-Mediated MMP-2 Activity During Bone Marrow Damage Stem Cells, September 1, 2005; 23(8): 1122 - 1134. [Abstract] [Full Text] [PDF]

				D. Metcalf, M. R. Carpinelli, C. Hyland, S. Mifsud, L. DiRago, N. A. Nicola, D. J. Hilton, and W. S. Alexander Anomalous megakaryocytopoiesis in mice with mutations in the c-Myb gene Blood, May 1, 2005; 105(9): 3480 - 3487. [Abstract] [Full Text] [PDF]

				A. Tomer Human marrow megakaryocyte differentiation: multiparameter correlative analysis identifies von Willebrand factor as a sensitive and distinctive marker for early (2N and 4N) megakaryocytes Blood, November 1, 2004; 104(9): 2722 - 2727. [Abstract] [Full Text] [PDF]

				A. Tomer Effects of anagrelide on in vivo megakaryocyte proliferation and maturation in essential thrombocythemia Blood, March 1, 2002; 99(5): 1602 - 1609. [Abstract] [Full Text] [PDF]

				G. D. Demetri Targeted Approaches for the Treatment of Thrombocytopenia Oncologist, October 1, 2001; 6(2008): 15 - 23. [Abstract] [Full Text] [PDF]